Infusional Cyclophosphamide, Doxorubicin and Etoposide in HIV-Related Non-Hodgkin's Lymphoma: a Follow-Up Report of a Highly Active Regimen

References

• Penn I. Cancers complicating organ transplantation. N. Engl. J. Med. 1990; 323: 1767
   PubMed Web of Science ®Google Scholar
• Rosenberg P. S., Gail M. H., Schrager L. K., et al. National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. J. AIDS 1991; 4: 392–97
   PubMed Web of Science ®Google Scholar
• Gail M. H., Pluda J. M., Rabkin C. S., et al. Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J. Nail. Cancer Inst. 1991; 83: 695–700
   PubMed Web of Science ®Google Scholar
• Pluda J. M., Vanzon D., Tosato G., et al. Factors which predict for the development of non-Hodgkin's lymphoma in patients with HIV infection receiving antiretroviral therapy. Blood 1991; 78: 285a, Abstract
   PubMedGoogle Scholar
• Levine A. M. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992; 80: 8–20
   PubMed Web of Science ®Google Scholar
• Lai G., Chen Y., Mickley L. A., Fojo A. T., Bates S. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int. J. Cancer 1991; 49: 696–703
   PubMed Web of Science ®Google Scholar
• Matsushima Y., Kanzawa F., Hoshi A. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother. Pharmacol. 1985; 14: 104–109
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Holden S. A., Eder J. P., Brann T. W., Jones S. M., Frei E. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res. 1989; 49: 5994–98
   PubMed Web of Science ®Google Scholar
• Solidoro A., Otero J., Vallejos C., Casanova L., Salas F., Pasco T., Quiroz L., Orlandini O., Marcial J. Intermittent continuous iv infusion of high-dose cyclophosphamide for remission induction in acute lymphocytic leukemia. Cancer Treat. Rep. 1981; 65: 213–18
   PubMedGoogle Scholar
• Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med. 1984; 310: 1353–56
   PubMed Web of Science ®Google Scholar
• Slevin M. L., Clark P. I., Joel S. P., Malik S., Osborne R. J., Gregory W. M., Lowe D. G., Reznek R. H., Wrigley P. F. M. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 1989; 7: 1333–39
   PubMed Web of Science ®Google Scholar
• Sparano J. A., Wiernik P. H., Leaf A., Dutcher J. P. Infusional cyclophosphamide, doxorubicin, and etoposide in patients with relapsed or resistant non-Hodgkin's lymphoma: Evidence for a schedule dependent effect favoring infusional administration of chemotherapy. J. Clin. Oncol. 1993; 11: 1071–79
   PubMed Web of Science ®Google Scholar
• Hansen M. M., Bloomfield C. D., Jorgensen J., et al. VP-16–213 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma. Cancer Treat. Rep. 1980; 64: 1135–37
   PubMedGoogle Scholar
• O'Dwyer P. J., Ley land-Jones B., Alonso M. T., et al. Etoposide (VP-16–213). Current status of an active anticancer drug. N. Engl. J. Med. 1985; 312: 692–700
   PubMed Web of Science ®Google Scholar
• Sparano J. A., Wiernik P. H., Strack M., Leaf A., Becker N., Valentine E. S. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-I-related non-Hodgkin's lymphoma: A highly active regimen. Blood 1993; 81: 2810–15
   PubMed Web of Science ®Google Scholar
• Sparano J. A., Wiernik P. H., Strack M., Leaf A. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-I-related non-Hodgkin's lymphoma: A highly active regimen. Proc. Am. Soc. Clin. Oncol. 1993; 12: 50, Abstract No. 3
   Google Scholar
• National Cancer Institute Sponsored Study of Classifications of non-Hodgkin's Lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112
   PubMed Web of Science ®Google Scholar
• Lokich J. J., Zipoli T. E., Moore C., Sonnenborn H., Paul S., Greene R. Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion. Cancer 1986; 58: 1020–23
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Gill P. S., Levine A. M., Krailo M., Rarick M. U., et al. AIDS-related malignant lymphoma: Results of prospective treatment trials. J. Clin. Oncol. 1987; 5: 1322–28
   PubMed Web of Science ®Google Scholar
• Kaplan L. D., Kahn J. O., Crowe S., Northfelt D., Neville P., Grossberg H., Abrams D. I., Tracey J., Mills J., Volberding P. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial. J. Clin. Oncol. 1990; 9: 929–40
   Web of Science ®Google Scholar
• Kaplan L. D., Abrams D. I., Geigal E., et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. J. Am. Med. Assoc 1989; 26: 719–24
   Google Scholar
• Levine A. M., Wemz J. C., Kaplan L., et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. J. Am. Med. Assoc 1991; 266: 84–88
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Oksenhendler E., Tirelli U., et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am. J. Med. 1993; 95: 188–96
   PubMed Web of Science ®Google Scholar
• Levine A. M., Sullivan-Halley J., Pike M. C., et al. Human immunodeficiency virus-related lymphoma: Prognostic factors predictive of survival. Cancer 1991; 68: 2466–72
   PubMed Web of Science ®Google Scholar
• Richman D. D., Fischl M., Grieco M. H., et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 1987; 317: 192–97
   PubMed Web of Science ®Google Scholar
• Hahn S., Pluda J., Shay J., et al. Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy, AZT, and GM-CSF. Proc. Am. Soc. Clin. Oncol. 1992; 11: 45, Abstract No. 6
   Google Scholar
• Faulds D., Brogden R. N. Didanosine. Drug Evaluation 1992; 44: 94–116
   Google Scholar
• Schacter L. P., Rozencweig M., Beltangady M., et al. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood 1992; 80: 2969–76
   PubMed Web of Science ®Google Scholar
• Kahn J. O., Lagakos S. W., Richman D., et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N. Engl. J. Med. 1992; 327: 581–87
   PubMed Web of Science ®Google Scholar
• Tirelli U., Errante D., Vaccher E., et al. Treatment of HIV-related non-Hodgkin's lymphoma (NHL) with chemotherapy (CT) and G-CSF: Reduction in the days of hospitalization and toxicity with concomitant overall reduction in cost. Proc. Am. Soc. Clin. Oncol. 1993; 12: 53, Abstract No. 13
   Google Scholar
• Groopman J. E., Feder D. Hematopoietic growth factors in AIDS. Semin. Onocol. 1992; 19: 408–14
   PubMed Web of Science ®Google Scholar
• Magrath I. T., Janus C., Edwards B. K., et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984; 63: 1102–11
   PubMed Web of Science ®Google Scholar
• Young R. C., Howser D. M., Anderson T., Fisher R. I., Jaffe E., De Vita V. T. Central nervous system complications of non-Hodgkin's lymphoma: The potential role for prophylactic therapy. Am. J. Med. 1979; 66: 435–43
   PubMed Web of Science ®Google Scholar
• Gibbs W. N., Lofters W. S., Campbell M., Hanchard B., La Grenade L., Cranston B., Hendriks J., Jaffe E. S., Saxinger C., Robert-Guroff M., Gallo R. C., Clark J., Blattner W. A. Non-Hodgkin's lymphoma in Jamaica and its relation to adult T-cell leukemia-lymphoma. Ann. Intern. Med. 1987; 106: 361–68
   PubMed Web of Science ®Google Scholar